Le Lézard
Classified in: Health
Subject: SVY

The Global Electroporation Instruments Market is expected to grow by USD 72.67 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period


NEW YORK, Jan. 28, 2020 /PRNewswire/ --

Global Electroporation Instruments Market 2020-2024
The analyst has been monitoring the global electroporation instruments market and it is poised to grow by USD 72.67 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on electroporation instruments market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Read the full report: https://www.reportlinker.com/p05576224/?utm_source=PRN

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising demand for monoclonal antibodies. In addition, high demand for biopharmaceuticals is anticipated to boost the growth of the electroporation instruments market as well.

Market Segmentation
The global electroporation instruments market is segmented as below:
End-user
? Pharma and biotech companies
? Academic and research institutes
? CROs

Geographic segmentation
? North America
? APAC
? Europe
? South America
? MEA

Key Trends for electroporation instruments market growth
This study identifies high demand for biopharmaceuticals as the prime reasons driving the electroporation instruments market growth during the next few years.
Prominent vendors in electroporation instruments market
We provide a detailed analysis of around 25 vendors operating in the electroporation instruments market, including some of the vendors such as BEX Co. Ltd., Bio-Rad Laboratories Inc., Celetrix LLC, Cellectricon AB, Eppendorf AG, Harvard Bioscience Inc., Lonza Group Ltd., MaxCyte Inc., Merck KGaA and Thermo Fisher Scientific Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Read the full report: https://www.reportlinker.com/p05576224/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...



News published on and distributed by: